Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
4.070
-0.100 (-2.40%)
At close: Jul 11, 2025, 4:00 PM
4.060
-0.010 (-0.25%)
After-hours: Jul 11, 2025, 6:49 PM EDT
Evotec SE Employees
Evotec SE had 4,740 employees as of December 31, 2024. The number of employees decreased by 321 or -6.34% compared to the previous year.
Employees
4,740
Change (1Y)
-321
Growth (1Y)
-6.34%
Revenue / Employee
$179,735
Profits / Employee
-$47,197
Market Cap
1.46B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4,740 | -321 | -6.34% |
| Dec 31, 2023 | 5,061 | 109 | 2.20% |
| Dec 31, 2022 | 4,952 | 754 | 17.96% |
| Dec 31, 2021 | 4,198 | 626 | 17.53% |
| Dec 31, 2020 | 3,572 | 542 | 17.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EVO News
- 17 days ago - Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury - Accesswire
- 2 months ago - Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments - Accesswire
- 2 months ago - Evotec SE (EVO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment - Accesswire
- 2 months ago - Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025 - Accesswire
- 2 months ago - Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb - Accesswire
- 3 months ago - Evotec SE (EVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results - Accesswire